Study of Capecitabine-Temozolomide(CapTem) With Yttrium-90 in Patients With Unresectable Metastatic Grade 2 Neuroendocrine Tumors

Conditions:   Neuroendocrine Tumor Grade 2;   Neuroendocrine Tumors Interventions:   Drug: Capecitabine Oral Product;   Drug: Temozolomide Oral Product;   Combination Product: transarterial radioembolization Sponsor:   University of Pennsylvania Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials